Differential proteomics analysis of low- and high-grade of astrocytoma using iTRAQ quantification.

摘要: Astrocytoma is one of the most common types brain tumor, which histologically and clinically classified into four grades (I-IV): I (pilocytic astrocytoma), II (diffuse III (anaplastic IV (glioblastoma multiforme). A higher grade astrocytoma represents a worse prognosis more aggressive. In this study, we compared differential proteome profile from to IV. The protein samples clinical specimens I, II, III, were analyzed by two-dimensional liquid chromatography-tandem mass spectrometry isobaric tags for relative absolute quantitation quantification. total 2,190 proteins identified. Compared astrocytoma, 173 (12.4%), 304 (14%), 462 (21.2%) aberrantly expressed in IV, respectively. By bioinformatics analysis, cell proliferation, invasion, angiogenesis-related pathways increase low- high-grade astrocytoma. Five differentially validated Western blot. Within them, matrix metalloproteinase-9 metalloproteinase inhibitor 1 upregulated glioblastoma multiforme group; whereas fibulin-2 -5 downregulated II/III/IV negative expression was significantly associated with advanced stage. Functional analysis showed that both may exert an antitumor effect inhibiting vitro migration/invasion glioma cells. New molecular biomarkers are likely be used accurate classification target drug development.